A Phase 3 interventional study of Pramipexole and Placebo in Parkinson Disease, sponsored by Boehringer Ingelheim. Completed at 70 sites in 14 countries. Open to participants aged 32 Years and older. Per ClinicalTrials.gov, last updated 2014-05-16.
Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies testing pramipexole in Parkinson Disease — none open to participants now, none under way, none of them phase 3. Pramipexole · Parkinson Disease.
Among the 26 studies testing pramipexole in Parkinson Disease, this one is the 8th largest by enrollment, is one of 5 that started in 2007, is one of 11 in phase 3, and was the 13th registered.
4,578 studies on the registry are indexed under Parkinson Disease; 1,087 are open to participants now.
Browse Parkinson Disease studies →None of the 26 studies testing pramipexole in Parkinson Disease is open now. The open studies under Parkinson Disease, anywhere →
Pramipexole: first FDA approval 1997 (MIRAPEX), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →
Of the 750 Parkinson Disease studies recruiting now, 312 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 190 take healthy volunteers.
This study: 32 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 2 · Phase 3 12 · Phase 4 10
First in 1998; this study’s year is marked. 5 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 391 is above the median of 40 across 3,355 interventional studies indexed under Parkinson Disease.
Median enrollment 224 across the 26 interventional studies. Of the 24 that completed or were terminated, 15 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 26 have an industry lead sponsor. The 10 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
42 studies in Parkinson Disease by Boehringer Ingelheim: none open now, none under way, none of them phase 3. Of 42 finished, 22 (52%) have results posted.
Among the 42 studies in Parkinson Disease by Boehringer Ingelheim, this one is the 7th largest by enrollment of the 20 interventional ones that give a count, is one of 7 that started in 2007, is one of 10 in phase 3, and was the 15th registered.
Boehringer Ingelheim’s Parkinson Disease studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 26 studies testing pramipexole in Parkinson Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Boehringer Ingelheim’s 42 in Parkinson Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The general aim of this study is to obtain long-term safety and tolerability data on pramipexole extended release (ER), in daily doses from 0.375mg to 4.5mg once daily (qd), in patients who have previously completed a pramipexole double-blind study in advanced Parkinson's disease (PD) (248.525 trial).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients to receive Pramipexole ER 0.375 - 4.5 mg in tablet form daily
Drug: Pramipexole
Patients to receive placebo tablets identical to Pramipexole ER tablets only during transfer phase
Drug: Placebo
Pramipexole ER 0.375 -4.5 mg
Placebo tablets identical to Pramipexole ER tablets
Percentage of Patients With Adverse Events, Adverse Drug Reactions, Serious Adverse Events
The aim of this study was to obtain long-term safety and tolerability data on pramipexole ER, in patients who have previously completed a pramipexole double blind study in advanced Parkinson's Disease (PD) (248.525 (NCT00466167)). Therefore these items were considered as a safety evaluation.
Time frame: 80 weeks
Patients Successfully Switched From Pramipexole (PPX) IR or ER to ER Assessed on UPDRS II+III
Unified Parkinson's Disease Rating Scale (UPDRS) Successfully switched means: UPDRS II+III baseline score \>20 without a relative worsening of UPDRS II+III score \> 15% from baseline or UPDRS II+III baseline score \<=20 without an absolute worsening of UPDRS II+III score \> 3 from baseline UPDRS II+III ranging from 0 (normal) to 160 (severe). UPDRS part II measures activities of daily living, part III measures motor symptoms
Time frame: One week
UPDRS II+III Change From Open Label (OL) Baseline
UPDRS II+III ranging from 0 (normal) to 160 (severe). UPDRS part II measures activities of daily living, part III measures motor symptoms
Time frame: OL Baseline and week 80
Number of Participants With UPDRS II+III Response
A response means an improvement of \>=20% in UPDRS II+III from OL baseline UPDRS II+III ranging from 0 (normal) to 160 (severe). UPDRS part II measures activities of daily living, part III measures motor symptoms
Time frame: Week 80
Number of Patients Successfully Switched From PPX IR or ER to ER Assessed on Off-time
A patient was considered as successfully switched if he/she has converted to ER without a worsening of off time by more than 12.5% from baseline. Off-time is based on patient diary data and describes a period when the patient experiences increased parkinsonian symptoms (e.g. immobility or inability to move with ease).
Time frame: One week
Percentage Off Time During Waking Hours Total Score: Change From Baseline
Percentage off-time based on patient diary data, percentage ranging from 0 (best case) to 100 (worst case). Off-time describes a period when the patient experiences increased parkinsonian symptoms (e.g. immobility or inability to move with ease). A negative change implies improvement
Time frame: Baseline and week 80
Number of Participants With Response in Percentage Off Time During Waking Hours
Response means \>=20% improvement relative to OL baseline in the % off-time during waking hours
Time frame: 80 weeks
Percentage on Time Without Dyskinesia During Waking Hours: Change From Baseline After 80 Weeks
Percentage on-time based on patient diary data, percentage ranging from 0 (worst case) to 100 (best case). On-time describes a period when the patient has no symptoms of off-time and is not asleep. A positive change implies improvement.
Time frame: Baseline and week 80
Percentage on Time With Non Troublesome Dyskinesia During Waking Hours: Change From Baseline After 80 Weeks
Percentage on-time with non troublesome dyskinesia based on patient diary data, percentage ranging from 0 (worst case) to 100 (best case). On-time describes a period when the patient has no symptoms of off-time and is not asleep. A positive change implies improvement
Time frame: Baseline and week 80
Percentage on Time Without Dyskinesia or With Non Troublesome Dyskinesia During Waking Hours: Change From Baseline After 80 Weeks
Percentage on-time without dyskinesia or with non troublesome dyskinesia based on patient diary data, percentage ranging from 0 (worst case) to 100 (best case). On-time describes a period when the patient has no symptoms of off-time and is not asleep. A positive change implies improvement
Time frame: Baseline and week 80
Percentage on Time With Troublesome Dyskinesia During Waking Hours: Change From Baseline After 80 Weeks
Percentage on-time with troublesome dyskinesia based on patient diary data, percentage ranging from 0 (worst case) to 100 (best case). On-time describes a period when the patient has no symptoms of off-time and is not asleep. A positive change implies improvement
Time frame: Baseline and week 80
Number of Participants With Response in CGI-I
Clinical Global Impression of Improvement (CGI-I), CGI-I scores ranging from '1' (very much improved) to '7' (very much worse). For patients previously treated with Placebo, all patients with at least "much improved" were considered as responders. For patients previously treated with PPX ER or IR, all patients with no change to very much improved were considered as responders
Time frame: 32 weeks
Number of Participants With Response in PGI-I
Patient Global Impression of Improvement (PGI-I), PGI-I scores ranging from '1' (very much better) to '7' (very much worse). For patients previously treated with Placebo, all patients with at least "much better" were considered as responders. For patients previously treated with PPX ER or IR, all patients with no change to very much better were considered as responders
Time frame: 32 weeks
Number of Participants With Response in PGI-I for Early Morning Off Symptoms
Patient Global Impression of Improvement (PGI-I) for early morning off symptoms, PGI-I scores ranging from '1' (very much better) to '7' (very much worse). For patients previously treated with Placebo, all patients with at least "much better" were considered as responders. For patients previously treated with PPX ER or IR, all patients with no change to very much better were considered as responders
Time frame: 32 weeks
UPDRS I Total Score and Change From OL Baseline at Week 80
UPDRS I ranging from 0 (normal) to 16 (severe). UPDRS I measures Mentation, Behavior and Mood
Time frame: OL baseline and week 80
UPDRS II Total Score and Change From OL Baseline at Week 80
UPDRS II ranging from 0 (normal) to 52 (severe). UPDRS Part II is calculated as the average of UPDRS part II at on and UPDRS part II at off-period for each of the 13 activities
Time frame: OL baseline and week 80
UPDRS III Total Score and Change From OL Baseline at Week 80
UPDRS III ranging from 0 (normal) to 108 (severe). UPDRS part III measures motor symptoms
Time frame: OL baseline and week 80
UPDRS IV Total Score and Change From OL Baseline at Week 80
UPDRS IV ranging from 0 (normal) to 23 (severe). UPDRS IV measures complications of therapy
Time frame: OL baseline and week 80
Parkinson Fatigue Scale (PFS-16) Score and Change From OL Baseline at Week 80
PFS-16 (Parkinson fatigue scale) ranging from 16 (better perceived health status) to 80 (severe symptoms of the disease) measuring aspects of fatigue that are relevant to patients with PD
Time frame: OL baseline and week 80
Number of Participants With L-dopa Daily Dose Change: Change From OL Baseline at Week 80
Time frame: OL baseline and week 80
Number of Participants With Changes in Pramipexole Doses After 80 Weeks Compared to Pramipexole Dose at OL Baseline
Time frame: OL baseline and week 80
Number of Participants With Serious Adverse Events
Time frame: 80 weeks
Supine Diastolic Blood Pressure, Baseline and Week 80, Vital Signs Treated Set
Time frame: OL Baseline and Week 80
Standing Diastolic Blood Pressure, Baseline and Week 80, Vital Signs Treated Set
Time frame: OL Baseline and Week 80
Supine Systolic Blood Pressure, Baseline and Week 80, Vital Signs Treated Set
Time frame: OL Baseline and Week 80
Standing Systolic Blood Pressure, Baseline and Week 80, Vital Signs Treated Set
Time frame: OL Baseline and Week 80
Supine Pulse Rate, Baseline and Week 80, Vital Signs Treated Set
Time frame: OL Baseline and Week 80
Standing Pulse Rate, Baseline and Week 80, Vital Signs Treated Set
Time frame: OL Baseline and Week 80
Body Weight of Female Patients, Baseline and Week 80, Vital Signs Treated Set
Time frame: OL Baseline and Week 80
Body Weight of Male Patients, Baseline and Week 80, Vital Signs Treated Set
Time frame: OL Baseline and Week 80
Epworth Sleepiness Scale (ESS), Baseline and End of Open Label, Treated Set
ESS Total score ranges from zero (best) to 24 (worst); scale has 8 items, each rated from zero (no chance of dozing) to 3 (high chance of dozing)
Time frame: OL Baseline and Week 80
Modified Minnesota Impulsive Disorder Interview (mMIDI), Frequency of Patients With at Least One Abnormal Behavior, Treated Set
The mMIDI is a semi-structured interview designed to assess impulsive control disorders. The scale was modified to focus behaviors of: pathological gambling, compulsive buying and compulsive sexual behavioral.
Time frame: Baseline, 80 weeks
| Milestone | PPX ER (Previous Placebo) | PPX ER (Previous PPX ER) | PPX ER (Previous PPX IR) |
|---|---|---|---|
| Started | 129 | 123 | 139 |
| Completed | 113 | 104 | 112 |
| Not completed | 16 | 19 | 27 |
| Withdrew: Adverse event | 11 | 7 | 14 |
| Withdrew: Protocol violation | 0 | 1 | 1 |
| Withdrew: Lost to follow-up | 0 | 3 | 4 |
| Withdrew: Withdrawal by subject | 5 | 5 | 6 |
| Withdrew: Other | 0 | 3 | 2 |
Unified Parkinson's Disease Rating Scale (UPDRS) Successfully switched means: UPDRS II+III baseline score \>20 without a relative worsening of UPDRS II+III score \> 15% from baseline or UPDRS II+III baseline score \<=20 without an absolute worsening of UPDRS II+III score \> 3 from baseline UPDRS II+III ranging from 0 (normal) to 160 (severe). UPDRS part II measures activities of daily living, part III measures motor symptoms
| Patients | PPX ER (Previous PPX ER) | PPX ER (Previous PPX IR) |
|---|---|---|
| Patients Successfully Switched From Pramipexole (PPX) IR or ER to ER Assessed on UPDRS II+III | 88 | 106 |
UPDRS II+III ranging from 0 (normal) to 160 (severe). UPDRS part II measures activities of daily living, part III measures motor symptoms
| Scores on a scale | PPX ER (Previous Placebo) | PPX ER (Previous PPX ER) | PPX ER (Previous PPX IR) |
|---|---|---|---|
| UPDRS II+III Change From Open Label (OL) Baseline | -3.6 ± 1.5 | 1.1 ± 1.6 | 2.5 ± 1.5 |
A response means an improvement of \>=20% in UPDRS II+III from OL baseline UPDRS II+III ranging from 0 (normal) to 160 (severe). UPDRS part II measures activities of daily living, part III measures motor symptoms
| Patients | PPX ER (Previous Placebo) | PPX ER (Previous PPX ER) | PPX ER (Previous PPX IR) |
|---|---|---|---|
| Number of Participants With UPDRS II+III Response | 35 | 30 | 31 |
A patient was considered as successfully switched if he/she has converted to ER without a worsening of off time by more than 12.5% from baseline. Off-time is based on patient diary data and describes a period when the patient experiences increased parkinsonian symptoms (e.g. immobility or inability to move with ease).
| Patients | PPX ER (Previous PPX ER) | PPX ER (Previous PPX IR) |
|---|---|---|
| Number of Patients Successfully Switched From PPX IR or ER to ER Assessed on Off-time | 57 | 70 |
Percentage off-time based on patient diary data, percentage ranging from 0 (best case) to 100 (worst case). Off-time describes a period when the patient experiences increased parkinsonian symptoms (e.g. immobility or inability to move with ease). A negative change implies improvement
| percentage during waking hours | PPX ER (Previous Placebo) | PPX ER (Previous PPX ER) | PPX ER (Previous PPX IR) |
|---|---|---|---|
| Percentage Off Time During Waking Hours Total Score: Change From Baseline | -1.5 ± 2.0 | -0.3 ± 2.1 | 1.7 ± 2.0 |
Response means \>=20% improvement relative to OL baseline in the % off-time during waking hours
| Patients | PPX ER (Previous Placebo) | PPX ER (Previous PPX ER) | PPX ER (Previous PPX IR) | Total PPX ER |
|---|---|---|---|---|
| Number of Participants With Response in Percentage Off Time During Waking Hours | 35 | 40 | 28 | 103 |
Percentage on-time based on patient diary data, percentage ranging from 0 (worst case) to 100 (best case). On-time describes a period when the patient has no symptoms of off-time and is not asleep. A positive change implies improvement.
| percentage during waking hours | PPX ER (Previous Placebo) | PPX ER (Previous PPX ER) | PPX ER (Previous PPX IR) |
|---|---|---|---|
| Percentage on Time Without Dyskinesia During Waking Hours: Change From Baseline After 80 Weeks | -1.6 ± 2.5 | 2.9 ± 2.7 | -2.0 ± 2.6 |
Percentage on-time with non troublesome dyskinesia based on patient diary data, percentage ranging from 0 (worst case) to 100 (best case). On-time describes a period when the patient has no symptoms of off-time and is not asleep. A positive change implies improvement
| percentage during waking hours | PPX ER (Previous Placebo) | PPX ER (Previous PPX ER) | PPX ER (Previous PPX IR) |
|---|---|---|---|
| Percentage on Time With Non Troublesome Dyskinesia During Waking Hours: Change From Baseline After 80 Weeks | 3.8 ± 1.8 | -2.7 ± 1.9 | 0.2 ± 1.8 |
Percentage on-time without dyskinesia or with non troublesome dyskinesia based on patient diary data, percentage ranging from 0 (worst case) to 100 (best case). On-time describes a period when the patient has no symptoms of off-time and is not asleep. A positive change implies improvement
| percentage during waking hours | PPX ER (Previous Placebo) | PPX ER (Previous PPX ER) | PPX ER (Previous PPX IR) |
|---|---|---|---|
| Percentage on Time Without Dyskinesia or With Non Troublesome Dyskinesia During Waking Hours: Change From Baseline After 80 Weeks | 1.8 ± 2.2 | 0.7 ± 2.3 | -0.9 ± 2.3 |
Percentage on-time with troublesome dyskinesia based on patient diary data, percentage ranging from 0 (worst case) to 100 (best case). On-time describes a period when the patient has no symptoms of off-time and is not asleep. A positive change implies improvement
| percentage during waking hours | PPX ER (Previous Placebo) | PPX ER (Previous PPX ER) | PPX ER (Previous PPX IR) |
|---|---|---|---|
| Percentage on Time With Troublesome Dyskinesia During Waking Hours: Change From Baseline After 80 Weeks | -0.4 ± 1.0 | -0.3 ± 1.1 | -0.7 ± 1.1 |
Clinical Global Impression of Improvement (CGI-I), CGI-I scores ranging from '1' (very much improved) to '7' (very much worse). For patients previously treated with Placebo, all patients with at least "much improved" were considered as responders. For patients previously treated with PPX ER or IR, all patients with no change to very much improved were considered as responders
| Patients | PPX ER (Previous Placebo) | PPX ER (Previous PPX ER) | PPX ER (Previous PPX IR) | Total PPX ER |
|---|---|---|---|---|
| Number of Participants With Response in CGI-I | 50 | 106 | 114 | 270 |
Patient Global Impression of Improvement (PGI-I), PGI-I scores ranging from '1' (very much better) to '7' (very much worse). For patients previously treated with Placebo, all patients with at least "much better" were considered as responders. For patients previously treated with PPX ER or IR, all patients with no change to very much better were considered as responders
| Patients | PPX ER (Previous Placebo) | PPX ER (Previous PPX ER) | PPX ER (Previous PPX IR) | Total PPX ER |
|---|---|---|---|---|
| Number of Participants With Response in PGI-I | 45 | 102 | 113 | 260 |
Patient Global Impression of Improvement (PGI-I) for early morning off symptoms, PGI-I scores ranging from '1' (very much better) to '7' (very much worse). For patients previously treated with Placebo, all patients with at least "much better" were considered as responders. For patients previously treated with PPX ER or IR, all patients with no change to very much better were considered as responders
| Patients | PPX ER (Previous Placebo) | PPX ER (Previous PPX ER) | PPX ER (Previous PPX IR) | Total PPX ER |
|---|---|---|---|---|
| Number of Participants With Response in PGI-I for Early Morning Off Symptoms | 45 | 103 | 112 | 260 |
UPDRS I ranging from 0 (normal) to 16 (severe). UPDRS I measures Mentation, Behavior and Mood
| units on a scale | PPX ER (Previous Placebo) | PPX ER (Previous PPX ER) | PPX ER (Previous PPX IR) |
|---|---|---|---|
| UPDRS I Total Score and Change From OL Baseline at Week 80 | 0.1 ± 0.2 | 0.5 ± 0.2 | 0.5 ± 0.2 |
UPDRS II ranging from 0 (normal) to 52 (severe). UPDRS Part II is calculated as the average of UPDRS part II at on and UPDRS part II at off-period for each of the 13 activities
| units on a scale | PPX ER (Previous Placebo) | PPX ER (Previous PPX ER) | PPX ER (Previous PPX IR) |
|---|---|---|---|
| UPDRS II Total Score and Change From OL Baseline at Week 80 | -0.4 ± 0.5 | 0.4 ± 0.6 | 1.0 ± 0.5 |
UPDRS III ranging from 0 (normal) to 108 (severe). UPDRS part III measures motor symptoms
| units on a scale | PPX ER (Previous Placebo) | PPX ER (Previous PPX ER) | PPX ER (Previous PPX IR) |
|---|---|---|---|
| UPDRS III Total Score and Change From OL Baseline at Week 80 | -3.1 ± 1.1 | 0.7 ± 1.1 | 1.3 ± 1.1 |
UPDRS IV ranging from 0 (normal) to 23 (severe). UPDRS IV measures complications of therapy
| Unit on a scale | PPX ER (Previous Placebo) | PPX ER (Previous PPX ER) | PPX ER (Previous PPX IR) |
|---|---|---|---|
| UPDRS IV Total Score and Change From OL Baseline at Week 80 | 0.0 ± 0.2 | -0.0 ± 0.3 | 0.2 ± 0.2 |
PFS-16 (Parkinson fatigue scale) ranging from 16 (better perceived health status) to 80 (severe symptoms of the disease) measuring aspects of fatigue that are relevant to patients with PD
| Unit on a scale | PPX ER (Previous Placebo) | PPX ER (Previous PPX ER) | PPX ER (Previous PPX IR) |
|---|---|---|---|
| Parkinson Fatigue Scale (PFS-16) Score and Change From OL Baseline at Week 80 | -0.3 ± 1.5 | 3.8 ± 1.6 | 3.5 ± 1.6 |
| Patients | PPX ER (Previous Placebo) | PPX ER (Previous PPX ER) | PPX ER (Previous PPX IR) | Total PPX ER |
|---|---|---|---|---|
| Decrease | 24 | 12 | 12 | 48 |
| Increase | 8 | 18 | 27 | 53 |
| No change | 93 | 84 | 93 | 270 |
| Patients | PPX ER (Previous Placebo) | PPX ER (Previous PPX ER) | PPX ER (Previous PPX IR) | Total PPX ER |
|---|---|---|---|---|
| Reduced | 56 | 33 | 26 | 115 |
| Unchanged | 40 | 43 | 53 | 136 |
| Increased | 29 | 39 | 47 | 115 |
| Patients | PPX ER (Previous Placebo) | PPX ER (Previous PPX ER) | PPX ER (Previous PPX IR) | Total PPX ER |
|---|---|---|---|---|
| Number of Participants With Serious Adverse Events | 14 | 11 | 14 | 39 |
The aim of this study was to obtain long-term safety and tolerability data on pramipexole ER, in patients who have previously completed a pramipexole double blind study in advanced Parkinson's Disease (PD) (248.525 (NCT00466167)). Therefore these items were considered as a safety evaluation.
| Percentage of participants | Placebo | PPX ER | PPX IR |
|---|---|---|---|
| Percentage of Patients with Adverse Events | 85.3 | 83.7 | 79.9 |
| Percentage of Patients with Adverse Drug Reactions | 52.7 | 48.8 | 45.3 |
| Percentage of Patients with Serious Adverse Events | 10.9 | 8.9 | 10.1 |
| mm Hg | PPX ER (Previous Placebo) | PPX ER (Previous PPX ER) | PPX ER (Previous PPX IR) |
|---|---|---|---|
| OL Baseline | 77.4 ± 8.9 | 77.3 ± 8.6 | 77.6 ± 9.4 |
| End of OL | 77.4 ± 8.9 | 78.3 ± 8.9 | 77.2 ± 8.3 |
| mm Hg | PPX ER (Previous Placebo) | PPX ER (Previous PPX ER) | PPX ER (Previous PPX IR) |
|---|---|---|---|
| OL Baseline | 77.8 ± 9.2 | 77.3 ± 9.1 | 77.6 ± 9.9 |
| End of OL | 77.6 ± 9.1 | 78.1 ± 9.3 | 76.4 ± 9.7 |
| mm Hg | PPX ER (Previous Placebo) | PPX ER (Previous PPX ER) | PPX ER (Previous PPX IR) |
|---|---|---|---|
| OL Baseline | 121.6 ± 12.2 | 124.5 ± 15.4 | 125.7 ± 14.8 |
| End of OL | 124.2 ± 13.5 | 123.8 ± 14.2 | 124.4 ± 14.7 |
| mm Hg | PPX ER (Previous Placebo) | PPX ER (Previous PPX ER) | PPX ER (Previous PPX IR) |
|---|---|---|---|
| OL Baseline | 120.2 ± 13.9 | 121.1 ± 16.4 | 120.9 ± 15.9 |
| End of OL | 121.9 ± 15.0 | 121.6 ± 14.3 | 120.5 ± 16.0 |
| beats per minute | PPX ER (Previous Placebo) | PPX ER (Previous PPX ER) | PPX ER (Previous PPX IR) |
|---|---|---|---|
| OL Baseline | 73.6 ± 9.6 | 72.6 ± 9.2 | 73.2 ± 9.0 |
| End of OL | 75.8 ± 9.0 | 74.2 ± 7.9 | 74.4 ± 10.0 |
| beats per minute | PPX ER (Previous Placebo) | PPX ER (Previous PPX ER) | PPX ER (Previous PPX IR) |
|---|---|---|---|
| OL Baseline | 78.3 ± 10.7 | 78.0 ± 9.5 | 77.7 ± 9.9 |
| End of OL | 79.3 ± 8.7 | 77.7 ± 7.5 | 78.8 ± 10.4 |
| kg | PPX ER (Previous Placebo) | PPX ER (Previous PPX ER) | PPX ER (Previous PPX IR) |
|---|---|---|---|
| OL Baseline | 61.9 ± 13.0 | 61.7 ± 14.0 | 63.8 ± 14.6 |
| End of OL | 63.6 ± 13.8 | 61.7 ± 15.0 | 63.6 ± 16.0 |
| kg | PPX ER (Previous Placebo) | PPX ER (Previous PPX ER) | PPX ER (Previous PPX IR) |
|---|---|---|---|
| OL Baseline | 73.0 ± 15.7 | 72.1 ± 12.2 | 70.8 ± 13.2 |
| End of OL | 73.9 ± 16.4 | 72.7 ± 12.5 | 72.0 ± 14.0 |
ESS Total score ranges from zero (best) to 24 (worst); scale has 8 items, each rated from zero (no chance of dozing) to 3 (high chance of dozing)
| units on a scale | PPX ER (Previous Placebo) | PPX ER (Previous PPX ER) | PPX ER (Previous PPX IR) |
|---|---|---|---|
| OL Baseline | 7.2 ± 4.6 | 8.1 ± 4.1 | 8.1 ± 4.9 |
| Change from baseline at end of OL | 0.5 ± 5.1 | 1.2 ± 4.7 | 1.2 ± 4.8 |
The mMIDI is a semi-structured interview designed to assess impulsive control disorders. The scale was modified to focus behaviors of: pathological gambling, compulsive buying and compulsive sexual behavioral.
| participants | PPX ER (Previous Placebo) | PPX ER (Previous PPX ER) | PPX ER (Previous PPX IR) |
|---|---|---|---|
| Abnormal behavior - pathological gambling | 0 | 0 | 0 |
| Abnormal behavior - compulsive buying | 2 | 0 | 2 |
| Abnormal behavior - compulsive sexual behavior | 2 | 2 | 0 |
Collected over 80 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PPX ER (Previous Placebo) | — | 14/129 (10.9%) | 87/129 (67.4%) |
| PPX ER (Previous PPX ER) | — | 11/123 (8.9%) | 74/123 (60.2%) |
| PPX ER (Previous PPX IR) | — | 14/139 (10.1%) | 81/139 (58.3%) |
| Total PPX ER | — | 39/391 (10%) | 242/391 (61.9%) |
| Event | PPX ER (Previous Placebo) | PPX ER (Previous PPX ER) | PPX ER (Previous PPX IR) | Total PPX ER |
|---|---|---|---|---|
| FallInjury, poisoning and procedural complications | 3/129 | 0/123 | 2/139 | 5/391 |
| Acute myocardial infarctionCardiac disorders | 0/129 | 1/123 | 0/139 | 1/391 |
| Coronary artery diseaseCardiac disorders | 0/129 | 1/123 | 0/139 | 1/391 |
| Multi-organ failureGeneral disorders | 0/129 | 1/123 | 0/139 | 1/391 |
| AppendicitisInfections and infestations | 0/129 | 1/123 | 0/139 | 1/391 |
| PneumoniaInfections and infestations | 1/129 | 1/123 | 1/139 | 3/391 |
| Septic shockInfections and infestations | 0/129 | 1/123 | 0/139 | 1/391 |
| UrosepsisInfections and infestations | 0/129 | 1/123 | 0/139 | 1/391 |
| Femoral neck fractureInjury, poisoning and procedural complications | 1/129 | 1/123 | 0/139 | 2/391 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 0/129 | 1/123 | 0/139 | 1/391 |
| Event | PPX ER (Previous Placebo) | PPX ER (Previous PPX ER) | PPX ER (Previous PPX IR) | Total PPX ER |
|---|---|---|---|---|
| DyskinesiaNervous system disorders | 41/129 | 33/123 | 32/139 | 106/391 |
| SomnolenceNervous system disorders | 15/129 | 18/123 | 19/139 | 52/391 |
| DizzinessNervous system disorders | 13/129 | 11/123 | 4/139 | 28/391 |
| InsomniaPsychiatric disorders | 10/129 | 10/123 | 7/139 | 27/391 |
| NauseaGastrointestinal disorders | 10/129 | 7/123 | 7/139 | 24/391 |
| HallucinationPsychiatric disorders | 10/129 | 6/123 | 6/139 | 22/391 |
| FallInjury, poisoning and procedural complications | 8/129 | 9/123 | 6/139 | 23/391 |
| CataractEye disorders | 9/129 | 8/123 | 6/139 | 23/391 |
| DystoniaNervous system disorders | 4/129 | 8/123 | 7/139 | 19/391 |
| Muscle rigidityMusculoskeletal and connective tissue disorders | 1/129 | 2/123 | 9/139 | 12/391 |
Treated Set, all patients dispensed study drug and documented to have taken at least one dose
| Age, Continuous(Years) | PPX ER (Previous Placebo) | PPX ER (Previous PPX ER) | PPX ER (Previous PPX IR) | Total |
|---|---|---|---|---|
| Mean | 61.3 ± 9.7 | 61.7 ± 9.8 | 61.8 ± 9.7 | 61.6 ± 9.7 |
| Sex: Female, Male(Participants) | PPX ER (Previous Placebo) | PPX ER (Previous PPX ER) | PPX ER (Previous PPX IR) | Total |
|---|---|---|---|---|
| Female | 58 | 55 | 65 | 178 |
| Male | 71 | 68 | 74 | 213 |
The record gives a start of Dec 2007 and a primary completion of Jun 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2011, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pramipexole